![N-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-6-iodoquinazolin-4-amine 231278-20-9 Lapatinib intermediate white powder buy - large image1](https://file.echemi.com/fileManage/upload/goodpicture/20220728/3r-4s-1-benzoyl-4-phenyl-3-triethylsilyloxy-2-azetidinone-149249-91-2-taxoid-side-chain-white-powder_b20220728152119283.jpg)
![N-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-6-iodoquinazolin-4-amine 231278-20-9 Lapatinib intermediate white powder buy - image1](https://file.echemi.com/fileManage/upload/goodpicture/20220728/s20220728152118964.jpg "N-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-6-iodoquinazolin-4-amine 231278-20-9 Lapatinib intermediate white powder")
N-[3-Chloro-4-(3-fluorobenzyloxy)-phenyl]-6-iodoquinazolin-4-amine 231278-20-9 Lapatinib intermediate white powder
231278-20-9
shanghai
1kg/bag
2023-03-03
calcium L-5-methyltetrahydrofolate
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodo-4-quinazolinamine
Other Name:4-Quinazolinamine,N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodo-;N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodo-4-quinazolinamine;6-Iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]quinazoline;N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-iodoquinazolin-4-amine;[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-iodoquinazolin-4-yl)amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-iodoquinazoline;N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazoline-4-amine
CAS No.:231278-20-9
Molecular Formula:C21H14ClFIN3O
InChIKeys:InChIKey=UHFPFDMMKYQMLC-UHFFFAOYSA-N
Molecular Weight:505.71
Exact Mass:505.71
EC Number:607-200-2
DSSTox ID:DTXSID10436351
HScode:2933990090
Categories:
Characteristics-
PSA:
47
XLogP3:6.3
Appearance:yellow solid
Density:1.7±0.1 g/cm3
Melting Point:222-224°C
Boiling Point:581.3°C at 760 mmHg
Flash Point:305.4±30.1 °C
Refractive Index:1.724
Water Solubility:Slightly soluble in water.
Vapor Pressure:0mmHg at 25°C
Hazard IdentificationClassification of the substance or mixture
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 4
GHS label elements, including precautionary statements
Pictogram(s) No symbol. Signal word No signal word
Hazard statement(s) H413 May cause long lasting harmful effects to aquatic life
Precautionary statement(s) Prevention P273 Avoid release to the environment.
Response none
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
calcium L-5-methyltetrahydrofolate
-
Location:
No.111,Qinxin Rd,Donggang Town,Xishan Dist,Wuxi,China.
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A
-
Average lead Time:
300
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2004
-
Certifications:
KOSEHR
Wuxi Taxus Pharmaceutical Co.,Ltd was established in 2004,and a bio-pharmaceutical company under the HODO Group which is the top 500 private enterprises . It is mainly engaged in the research, development, production and sales of paclitaxel-based anti-tumor drugs. The complete industrial chain was established,from the cultivation of yew resources to the processing of yew branches and leaves, paclitaxel primary products, paclitaxel series of raw materials and intermediates to preparations . Products include paclitaxel, docetaxel, cabazitaxel, 10-DAB, oxaliplatin, dresian hydrochloride, allopurinol, L-5-methylfolate, L-5-methylfolate, etc. API, and paclitaxel injection.
The company has strong technical strength. In 2018, the company established the Hongdoushan International Pharmaceutical Research and Development Company in New York, focusing on the research and development and introduction of anticancer drugs. At present, the Hongdoushan research and development center hires the Doctor returned from abroad to lead the research and development of new products, and currently has more than 30 senior engineers. What’s more, the R&D Center has established close cooperative relations with Jiangsu Academy of Agricultural Sciences, Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tsinghua University, and foreign research institutes.
The company's paclitaxel API has obtained the US DMF registration number (25759), and is registered in Korea, India, Iran, Russia, Belarus and other countries. It is sold at home and abroad, mainly exported to India, South America, Russia, Egypt and other countries and regions,and praised
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product